GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Net Margin %

CanSino Biologics (HKSE:06185) Net Margin % : -32.30% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. CanSino Biologics's Net Income for the three months ended in Jun. 2024 was HK$-59.5 Mil. CanSino Biologics's Revenue for the three months ended in Jun. 2024 was HK$184.2 Mil. Therefore, CanSino Biologics's net margin for the quarter that ended in Jun. 2024 was -32.30%.

The historical rank and industry rank for CanSino Biologics's Net Margin % or its related term are showing as below:

HKSE:06185' s Net Margin % Range Over the Past 10 Years
Min: -12214.46   Med: -429.55   Max: 44.52
Current: -142.92


HKSE:06185's Net Margin % is ranked worse than
90.19% of 989 companies
in the Drug Manufacturers industry
Industry Median: 4.3 vs HKSE:06185: -142.92

CanSino Biologics Net Margin % Historical Data

The historical data trend for CanSino Biologics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Net Margin % Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial - -2,138.87 44.52 -88.21 -429.55

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 883.24 -92.92 -293.54 -148.84 -32.30

Competitive Comparison of CanSino Biologics's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Net Margin % distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Net Margin % falls into.



CanSino Biologics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

CanSino Biologics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-1621.781/377.553
=-429.55 %

CanSino Biologics's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin=Net Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-59.508/184.237
=-32.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CanSino Biologics  (HKSE:06185) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


CanSino Biologics Net Margin % Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Executives
Yu Xuefeng 2501 Other
Chao Shou Bai 2202 Interest of your spouse
Mao Helen Huihua 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Zhu Tao
Orbimed Capital Llc 2102 Investment manager

CanSino Biologics Headlines

No Headlines